Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape

References

• Cortés J, Cescon DW, Rugo HS, et al. LBA16 KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Abstr Book ESMO Congr 2021; 2021 Sep 16 – 21;32:S1289–S1290.
   Google Scholar
• Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983–993.
   Google Scholar
• Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–690.
   Google Scholar
• Li CH, Karantza V, Aktan G, et al. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 2019;21:143.
   Google Scholar
• Lipson EJ, Drake CG. Ipilimumab: an Anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17:6958–6962.
   Google Scholar
• Marra A, Trapani D, Viale G, et al. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. npj Breast Cancer. 2020;6:54.
   Google Scholar
• Woodruff MFA, Symes MO. The use of immunologically competent cells in the treatment of cancer: experiments with a transplantable mouse tumour. Br J Cancer. 1962;16:707–715.
   Google Scholar
• Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499–511.
   Google Scholar
• El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group. npj Breast Cancer. 2021;7:150.
   Google Scholar
• Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Cancer Netw. 2020;18:479–489.
   Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405–411.
   Google Scholar
• Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460–2467.
   Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–686.
   Google Scholar
• Passaro A, Brahmer J, Antonia S, et al. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol. 2022;40:598–610.
   Google Scholar
• Schettini F, Venturini S, Giuliano M, et al. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Cancer Treat Rev. 2022;111:102468.
   Google Scholar
• Ji Q, Ding J, Hao M, et al. Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:795650.
   Google Scholar
• Fumet J-D, Limagne E, Thibaudin M, et al. Immunogenic cell death and elimination of immunosuppressive cells: a double-edged sword of chemotherapy. Cancers (Basel). 2020;12:2637.
   Google Scholar
• Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920–928.
   Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.
   Google Scholar
• Hayashi K, Nikolos F, Lee YC, et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020;11:6299.
   Google Scholar
• Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–648.
   Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436–443.
   Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   Google Scholar
• Valenza C, Antonarelli G, Giugliano F, et al. Emerging treatment landscape of non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2022;22:717–734.
   Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma. Cancer. 2009;115:5339–5348.
   Google Scholar
• Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45–56.
   Google Scholar
• Engel AL, Holt GE, Lu H. The pharmacokinetics of toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol. 2011;4:275–289.
   Google Scholar
• Albershardt TC, Leleux J, Parsons AJ, et al. Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors. Npj Vaccines. 2020;5:50.
   Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–566.
   Google Scholar
• Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526–1535.
   Google Scholar
• Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol [Internet]. 2020;10. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2020.00570
   Google Scholar
• Liu YL, Selenica P, Zhou Q, et al. BRCA mutations, homologous dna repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer. JCO Precis Oncol. 2020;665–679. DOI:10.1200/PO.20.00069
   Google Scholar
• Barroso-Sousa R, Forman J, Collier K, et al. Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit. JCO Precis Oncol. 2022;e2100413. DOI:10.1200/PO.21.00413
   Google Scholar
• Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–661.
   Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711–3720.
   Google Scholar
• Wang W, Han D, Cai Q, et al. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022;13:245.
   Google Scholar
• Smith AE, Ferraro E, Safonov A, et al. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021;12:6667.
   Google Scholar
• Brufsky A, Kim SB, Zvirbule Ž, et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Ann Oncol. 2021;32:652–660.
   Google Scholar
• Loi S, Dushyanthen S, Beavis PA, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22:1499–1509.
   Google Scholar
• Bertucci F, Finetti P, Simeone I, et al. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br J Cancer. 2018;119:1383–1391.
   Google Scholar
• Poon E, Mullins S, Watkins A, et al. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. J Immunother Cancer. 2017;5:63.
   Google Scholar
• Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T Cell–Mediated immunotherapy. Cancer Discov. 2016;6:202–216.
   Google Scholar
• Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475–1485.
   Google Scholar
• Lehmann BD, Colaprico A, Silva TC, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12:6276.
   Google Scholar
• Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-Cells in malignant effusions. Anticancer Res. 2009;29:881.
   Google Scholar
• Gerber H-P, Sapra P, Loganzo F, et al. Combining antibody–drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6.
   Google Scholar
• Tarantino P, Morganti S, Uliano J, et al. Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opin Biol Ther. 2021;21:127–133.
   Google Scholar
• Lopez S, Perrone E, Bellone S, et al. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget. 2020;11:560–570.
   Google Scholar
• Nicolò E, Giugliano F, Ascione L, et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev. 2022;106:102395.
   Google Scholar
• Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113.
   Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121.
   Google Scholar
• Cortés J, André F, Gonçalves A, et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 2019;15:1951–1961.
   Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004.
   Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with Pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–567.
   Google Scholar
• Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol [Internet]. [cited 2022 Sep 6 2022]; 33:1149–1158.
   Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–1100.
   Google Scholar
• Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study☆. Ann Oncol. 2022;33:534–543.
   Google Scholar
• Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). J Clin Oncol. 2022;40:513–513.
   Google Scholar
• Santa-Maria CA, Kato T, Park J-H, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018;9:18985–18996.
   Google Scholar
• Barroso-Sousa R, Li T, Reddy S, et al. Abstract GS2-10: Nimbus: a phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). Cancer Res. 2022;82:GS2–10.
   Google Scholar
• Adams S, Othus M, Patel SP, et al. Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36). J Clin Oncol. 2020;38:1073–1073.
   Google Scholar
• Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57.
   Google Scholar
• Vijayan D, Young A, Teng MWL, et al. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709–724.
   Google Scholar
• Debien V, Maurer C, Aftimos P, et al. Abstract OT1-18-02: first-line chemo-immunotherapy with durvalumab, paclitaxel and carboplatin with or without anti-CD73 antibody oleclumab in advanced or metastatic triple-negative breast cancer: preliminary results of the randomized phase II SYNERGY trial. Cancer Res. 2022;82:OT1-18–02.
   Google Scholar
• Rouanne M, Zitvogel L, Marabelle A. Pegylated engineered IL2 plus Anti–PD-1 monoclonal antibody: the nectar comes from the combination. Cancer Discov. 2020;10:1097–1099.
   Google Scholar
• Diab A, Hurwitz ME, Tannir N, et al. PIVOT-02: a phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Ann Oncol. 2017;28:v426–v427.
   Google Scholar
• Meric-Bernstam F, Sandhu SK, Hamid O, et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J Clin Oncol. 2019;37:2507–2507.
   Google Scholar
• Chan ASH, Kangas TO, Qiu X, et al. Imprime PGG enhances anti-tumor effects of tumor-targeting, anti-angiogenic, and immune checkpoint inhibitor antibodies. Front Oncol [Internet]. 2022;12. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2022.869078
   Google Scholar
• O’Day SJ, Borges VF, Chmielowski B, et al. Abstract CT073: IMPRIME 1 (NCT02981303): a novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG. Cancer Res. 2020;80:CT073.
   Google Scholar
• Chien AJ, Soliman HH, Ewing CA, et al. Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: results from the I-SPY 2 trial. J Clin Oncol. 2021;39:508.
   Google Scholar
• Zhu S-Y, K-D Y. Breast cancer vaccines: disappointing or promising? Front Immunol [Internet]. 2022;13. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.828386
   Google Scholar
• den Brok WD, Schrader KA, Sun S, et al. Homologous recombination deficiency in breast cancer: a clinical review. JCO Precis Oncol. 2017;1:1–13.
   Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–763.
   Google Scholar
• Domchek SM, Postel-Vinay S, Im S-A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–1164.
   Google Scholar
• Domchek S, Postel-Vinay S, Bang Y-J, et al. Abstract PD6-11: an open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). Cancer Res. 2018;78:D6–11.
   Google Scholar
• Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of Niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 2019;5:1132–1140.
   Google Scholar
• Yap TA, Konstantinopoulos P, Telli ML, et al. Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: results from advanced breast cancer cohorts. Cancer Res. 2020;80: P1-19–03.
   Google Scholar
• Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39:989–998.e5.
   Google Scholar
• Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88.
   Google Scholar
• Jiang Y-Z, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428–440.e5.
   Google Scholar
• Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   Google Scholar
• Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–887.
   Google Scholar
• Dent R, Kim S-B, Oliveira M, et al. IPATunity130: a pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC). J Clin Oncol. 2018;36: TPS1117.
   Google Scholar
• Schmid P, Loirat D, Savas P, et al. Abstract CT049: phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2019;79:CT049.
   Google Scholar
• Schmid P, Savas P, Espinosa E, et al. Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Cancer Res. 2021;81:S12–28.
   Google Scholar
• Schmid P, Loirat D, Savas P, et al. Abstract PD14-03: molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC). Cancer Res. 2021;81:D14–03.
   Google Scholar
• Yuan Y, Yost SE, Frankel PH, et al. A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2021;39:1078.
   Google Scholar
• Marmé F, Stickeler E, Furlanetto J, et al. Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. J Clin Oncol. 2021;39: TPS602.
   Google Scholar
• Chen L, Zhimin S, Wang Z, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): a prospective, single-arm, phase 2 study. J Clin Oncol. 2021;39:1007.
   Google Scholar
• Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020;8:e000696.
   Google Scholar
• Liu J, Wang Y, Tian Z, et al. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 2022;13:3011.
   Google Scholar
• Moehler M, Shitara K, Garrido M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: first results of the CheckMate 649 study. The Lancet. 2021;398(10294):27–40.
   Google Scholar
• Ozaki Y, Mukohara T, Tsurutani J, et al. Abstract PD1-03: a multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial. Cancer Res. 2020;80:D1–03.
   Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–1541.
   Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387:9–20.
   Google Scholar
• Schmid P, Im S-A, Armstrong A, et al. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol. 2021;39:1023.
   Google Scholar
• Krop I, Juric D, Shimizu T, et al. Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study. Cancer Res. 2022;82:GS1–05.
   Google Scholar
• Schmid P. Datopotamab Deruxtecan + Durvalumab as first-line treatment for unresectable locally advanced/metastatic triple-negative breast. Annals of Oncology. 3(suppl_3):S194–S223.
   Google Scholar
• Han H, Diab S, Alemany C, et al. Abstract PD1-06: open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer. Cancer Res. 2020;80: D1-06-PD1-06.
   Google Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299–309.
   Google Scholar
• Arora S, Velichinskii R, Lesh RW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36:2638–2678.
   Google Scholar
• Scott M, Scorer P, Barker C, et al. Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Ann Oncol. 2019;30:iii4.
   Google Scholar
• Noske A, Ammann J, Wagner D-C, et al. 359P - reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC). Abstr Book 44th ESMO Congr ESMO 2019; 27 Sept –1 Oct 2019. Barc Spain. 2019. 30. p. v130–v131.
   Google Scholar
• Rugo HS, Loi S, Adams S, et al. Performance of PD-L1 immunohistochemistry assays in unresectable locally advanced or metastatic triple-negative breast cancer: post hoc analysis of Impassion. Ann Oncol. 2019;130:13.
   Google Scholar
• Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6:41228–41236.
   Google Scholar
• Bachelot T, Filleron T, Bieche I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021;27:250–255.
   Google Scholar
• Gobbini E, Charles J, Toffart A-C, et al. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bull Cancer (Paris). 2020;107:1098–1107.
   Google Scholar
• Zaremba A, Eggermont AMM, Robert C, et al. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer. 2021;155:268–280.
   Google Scholar
• Bimbatti D, Maruzzo M, Pierantoni F, et al. Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. Crit Rev Oncol Hematol. 2022;170:103579.
   Google Scholar
• Metro G, Signorelli D. Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? Lung Cancer Manag. 2019;8:LMT18.
   Google Scholar
• Zhou J, Wang T, Bian L, et al. Benefit with re-challenge of immune checkpoint inhibitors in patient with metastatic triple-negative breast cancer: a case report. Transl Breast Cancer Res 2021 April [cited 2020 Dec 31];2:14. Available from: https://tbcr.amegroups.com/article/view/50386
   Google Scholar
• Otani Y, Mori K, Morikawa N, et al. Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report. Immunotherapy. 2021;13:189–194.
   Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.
   Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–108.
   Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
   Google Scholar